La cadena de opciones muestra datos clave de las opciones de acciones de Cyclacel Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cyclacel Pharmaceuticals..

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Bolsa, Cadena de Opciones

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Earnings

News

CYCC

Cyclacel Pharmaceuticals Reports Q4 EPS Of $(0.33)

Cyclacel Pharmaceuticals Announces $1M Private Placement Offering Of Convertible Series E Preferred Stock To Certain Accredited Investors

Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.
Pursuant to the closing of a Securities Purchase Agreement (the "Agreement") between Cyclacel's former interim chief executive officer David Lazar ("Seller") and Datuk Dr. Doris Wong Sing Ee ("Purchaser"), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the "Series C") and such number of the 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the "Series D") held by Seller so that Purchaser owns 70% of the issued and outstanding shares of Cyclacel, which resulted in the issuance of 1,745,262 shares of Series D (collectively, the Series C and Series D, the "Securities"). The transaction contemplated by the Agreement closed on February 26, 2025 (the "Closing Date") at which point Purchaser purchased and succeeded to all of Seller's rights and interests under the securities purchase agreement between Seller and Cyclacel dated January 2, 2025.
Purchaser acquired the Securities for a total consideration of $6,300,000 (the "Purchase Price") less a holdback amount of $100,000 (the "Holdback Amount") to the escrow agent. The Purchase Price included a cash brokerage fee of $800,000. The Holdback Amount will be held by Purchaser for 120 days from the Closing Date to satisfy any indemnity and other agreed upon claims and expenses.
On the Closing Date, Seller issued written notice to Cyclacel to exercise the conversion rights related to the Series C and Series D shares into the common stock, par value $0.001 per share (the "Common Stock") of Cyclacel registered in Purchaser's name, as follows: (i) 1,000,000 shares of Series C into 2,650,000 shares of Common Stock and (ii) 1,745,262 shares of Series D into 191,978,820 shares of Common Stock. As of the Closing Date, Purchaser has become the new controlling shareholder of Cyclacel.
At the same time, David Lazar resigned as interim chief executive officer and secretary and Datuk Dr. Doris Wong Sing Ee was elected as Chief Executive Officer and Executive Director of Cyclacel. Cyclacel also announced the appointment of Kiu Cu Seng as Executive Director, Secretary and Chief Financial Officer and, in such role, he will serve as the Company's co-principal financial officer and co-principal accounting officer along with David Lazar until the effective date of his resignation on the earlier of the filing date of the Company's annual report on Form 10-K for the fiscal year ended December 31, 2024 or March 31, 2025.

Management

CYCCP

Cyclacel Pharmaceuticals Announces Leadership Change After $6.3M Share Purchase; Datuk Dr. Doris Wong Sing Ee Acquires 70% Stake And Becomes CEO; David Lazar Resigns As Interim CEO, Kiu Cu Seng Appointed CFO

Cyclacel To Acquire Plogosertib, A Phase 1 Polo-Like Kinase Inhibitor; Develop New Oral Formulation

<h3>Gainers</h3>
<ul>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock increased by 84.5% to $1.53 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.1 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares increased by 30.3% to $0.21. The company's market cap stands at $1.4 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock rose 21.57% to $0.42. The company's market cap stands at $14.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 13.2% to $1.2. The market value of their outstanding shares is at $33.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock rose 13.08% to $4.49. The market value of their outstanding shares is at $3.3 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares rose 11.23% to $1.98. The company's market cap stands at $35.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 58.2% to $0.61 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock decreased by 17.72% to $2.23. The market value of their outstanding shares is at $21.0 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 16.09% to $0.36. The company's market cap stands at $8.3 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock fell 15.79% to $4.0. The market value of their outstanding shares is at $231.5 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock decreased by 15.36% to $0.54. The company's market cap stands at $4.5 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 13.16% to $0.33. The market value of their outstanding shares is at $3.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIRS

BACK

BIVI

GELS

HEPA

KLTO

OCEA

ONCO

ONMD

Qualigen Therapeutics, Inc. - Common Stock

QLGN

STSS

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 86.0% to $0.69 during Friday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares moved upwards by 70.83% to $0.59. The market value of their outstanding shares is at $2.8 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares increased by 34.87% to $0.88. The company's market cap stands at $7.2 million. </li>
<li>Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) stock moved upwards by 26.66% to $18.05. The company's market cap stands at $58.6 million. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) shares moved upwards by 22.2% to $0.31. The company's market cap stands at $31.8 million. </li>
<li>Immatics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMTX#NASDAQ">IMTX</a>) shares rose 16.03% to $8.61. The company's market cap stands at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock decreased by 16.2% to $0.58 during Friday's pre-market session. The company's market cap stands at $12.1 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares declined by 12.86% to $5.15. The company's market cap stands at $10.5 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares fell 11.76% to $0.11. The market value of their outstanding shares is at $11.7 million. </li>
<li>Akso Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares declined by 11.43% to $1.24. The company's market cap stands at $494.5 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock declined by 10.76% to $0.33. The market value of their outstanding shares is at $16.9 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 9.94% to $0.63. The company's market cap stands at $14.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNGO

COEP

CTCX

ERNA

EYEN

IMTX

SCPX

SRZN

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite surging more than 1% on Friday.
The Dow traded up 0.61% to 42,648.40 while the NASDAQ gained 1.44% to 19,559.00. The S&amp;P 500 also rose, gaining, 1.07% to 5,931.10.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/42785083/how-to-earn-500-a-month-from-kb-home-stock-ahead-of-q4-earnings">How To Earn $500 A Month From KB Home Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Utilities shares jumped by 1.2% on Friday.
In trading on Friday, financial shares rose by just 0.1%.
Top Headline
The ISM manufacturing PMI increased by 0.9 points to a reading of 49.3 in December, topping market estimates of 48.4.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cerence Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) shares shot up 66% to $13.18 after the company announced an expanded collaboration with NVIDIA to advance its CaLLM family of language models.</li>
<li>Shares of N2OFF, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>)got a boost, surging 202% to $3.2401 after the company announced it executed a binding LOI with Solterra Brand Services Italy to develop two 98MWP battery storage projects in Sicily.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares were also up, gaining 64% to $0.6094 after the company announced a securities purchase agreement with investor David Lazar for the sale of Series C and Series D Convertible Preferred Stock for $3.1 million in gross proceeds.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) shares dropped 22% to $36.62.</li>
<li>Shares of T Stamp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) were down 25% to $0.5150. The company announced it will implement a 1-for-15 reverse stock split.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) was down, falling 31% to $0.4765. Carmell announced closing of previously announced PIPE investment from existing and new investors to support commercial build-out.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $73.69 while gold traded down 0.4% at $2,659.60.
Silver traded up 1.2% to $30.255 on Friday, while copper rose 0.6% to $4.0495.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.48%, Germany's DAX 40 fell 0.55% and France's CAC 40 dipped 1.37%. Spain's IBEX 35 Index fell 0.19%, while London's FTSE 100 fell 0.33%.
Asia Pacific Markets
Asian markets closed mixed on Friday, with China's Shanghai Composite Index falling 1.57%, Hong Kong's Hang Seng Index gaining 0.70% and India's BSE Sensex falling 0.90%.
Economics
The ISM manufacturing PMI increased by 0.9 points to a reading of 49.3 in December, topping market estimates of 48.4.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42785203/tesla-to-351-here-are-10-top-analyst-forecasts-for-friday">Tesla To $351? Here Are 10 Top Analyst Forecasts For Friday</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CRNC

DOGZ

IDAI

NITO

Nasdaq Surges Over 1%; Cerence Shares Spike Higher

Cyclacel Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares are trading higher by 65% to 61 cents during Friday&#8217;s session after the company announced a securities purchase agreement with investor David Lazar for the sale of Series C and Series D Convertible Preferred Stock for <a href="https://www.benzinga.com/pressreleases/25/01/g42784853/cyclacel-pharmaceuticals-announces-agreement-for-the-acquisition-of-preferred-stock-by-david-lazar">$3.1 million in gross proceeds</a>.
What To Know: Lazar will acquire 1 million shares of Series C Convertible Preferred Stock for $1 million initially, with the potential to convert these shares into common stock, subject to a 5% ownership cap pending stockholder approval. 
Upon approval, a second transaction will involve 2.1 million shares of Series D Convertible Preferred Stock for $2.1 million, convertible into 110 shares of common stock per preferred share.
As part of the agreement, the board was restructured, with David Lazar assuming the role of interim CEO. Cyclacel also entered a Warrant Exchange Agreement, converting existing warrants into 24.8 million shares of common stock and $1.1 million cash. 
The company says it faces challenges meeting Nasdaq&#8217;s equity requirements, with a February 2025 compliance deadline, and continues exploring strategic alternatives.
Read Also: <a href="https://www.benzinga.com/25/01/42784518/hindenburg-slams-carvana-are-investors-ignoring-the-red-flags">Carvana Chart Weakens As Momentum Indicators Turn Bearish, Short Report Hits</a>
<h2 class="wp-block-heading">How To Buy CYCC</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Cyclacel Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CYCC has a 52-week high of $4.00 and a 52-week low of $0.31.

Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Friday.
Following the market opening, the Dow traded up 0.31% to 42,524.52 while the NASDAQ gained 0.88% to 19,450.89. The S&amp;P 500 also rose, gaining, 0.51% to 5,898.53.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/42785083/how-to-earn-500-a-month-from-kb-home-stock-ahead-of-q4-earnings">How To Earn $500 A Month From KB Home Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Information technology shares rose by 1.1% on Friday.
In trading on Friday, financial shares fell by 0.2%.
Top Headline
The ISM manufacturing PMI increased by 0.9 points to a reading of 49.3 in December, topping market estimates of 48.4.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares shot up 234% to $0.6164.</li>
<li>Shares of N2OFF, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>)got a boost, surging 143% to $2.60 after the company announced it executed a binding LOI with Solterra Brand Services Italy to develop two 98MWP battery storage projects in Sicily.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares were also up, gaining 90% to $0.7028 after the company announced a securities purchase agreement with investor David Lazar for the sale of Series C and Series D Convertible Preferred Stock for $3.1 million in gross proceeds.</li>
</ul>
Equities Trading DOWN
<ul>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) shares dropped 38% to $0.40.</li>
<li>Shares of T Stamp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) were down 32% to $0.4701. The company announced it will implement a 1-for-15 reverse stock split.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) was down, falling 30% to $0.4878. Carmell announced closing of previously announced PIPE investment from existing and new investors to support commercial build-out.</li>
</ul>
Commodities In commodity news, oil traded up 0.4% to $73.42 while gold traded down 0.3% at $2,662.40.
Silver traded up 1.2% to $30.265 on Friday, while copper rose 0.7% to $4.0540.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX 40 fell 0.5% and France's CAC 40 dipped 1.3%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 fell 0.3%.
Asia Pacific Markets
Asian markets closed mixed on Friday, with China's Shanghai Composite Index falling 1.57%, Hong Kong's Hang Seng Index gaining 0.70% and India's BSE Sensex falling 0.90%.
Economics
The ISM manufacturing PMI increased by 0.9 points to a reading of 49.3 in December, topping market estimates of 48.4.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42785203/tesla-to-351-here-are-10-top-analyst-forecasts-for-friday">Tesla To $351? Here Are 10 Top Analyst Forecasts For Friday</a></li>
</ul>

Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December

WIIM

Cyclacel Pharmaceuticals shares are trading higher after the company announced a securities purchase agreement with investor David Lazar for the sale of Series C and Series D Convertible Preferred Stock for $3.1 million in gross proceeds

Cyclacel Pharmaceuticals  Enters Securities Purchase Agreement With Investor David Lazar For the Purchase Of 1M Shares Of Series C Convertible Preferred Stock And 2,100,000 Shares Of Series D Convertible Preferred Stock; Gross Proceeds $3.1M

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder.
The Company's Board of Directors is reviewing a range of appropriate strategies to realize value from its assets. The Board has directed management to reduce operating costs while such alternatives are being explored. There can be no assurance that the exploration of strategic alternatives will result in any agreement or transaction, or as to the timing of any such agreement or transaction. Further, there can be no assurance that the Company will be able to reach an agreement, or consummate a transaction, with Mr. Lazar or receive the required consent of an existing securityholder to any such transaction.
As previously disclosed, the Company does not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. In the event that the Company is not able to enter into a strategic transaction and/or secure additional funding, it may be forced to cease all business operations. In such event, the Company's stockholders may lose a part or all of their investment in the Company.

Cyclacel Pharmaceuticals Announces Its Exploration Of Potential Strategic Alternatives On An Expedited Basis In Order To Preserve The Company's Cash, Including A Potential Transaction With Investor David Lazar Of Activist Investing, LLC

Shares of DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/quote/DLO/earnings">third-quarter revenue results</a>.
DLocal reported quarterly earnings of 9 cents per share which missed the analyst consensus estimate of 11 cents per share. The company reported quarterly sales of $185.774 million which beat the analyst consensus estimate of $181.463 million.
DLocal shares jumped 18.3% to $10.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 91.1% to $0.0472 in pre-market trading after surging 32% on Wednesday.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) rose 40% to $0.0339 in pre-market trading.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) gained 35.7% to $0.0777 in pre-market trading after gaining 18% on Wednesday.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) gained 28.7% to $0.5335 in pre-market trading.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) gained 26.9% to $8.25 in pre-market trading after the company reported second-quarter results.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) climbed 25.8% to $3.34 in pre-market trading after jumping more than 92% on Wednesday.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) gained 20.5% to $21.40 in pre-market trading. Zeta Global increased its share repurchase program with $100 million buyback authorization through 2026.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) gained 17.7% to $0.5301 in pre-market trading after dipping 58% on Wednesday.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) gained 14.6% to $2.04 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Calidi Biotherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) shares tumbled 27% to $2.47 in pre-market trading after the company announced a proposed public offering.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares fell 26.5% to $0.1329 in pre-market trading after jumping over 40% on Wednesday.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) declined 25.8% to $38.45 in pre-market trading after the company reported worse-than-expected third-quarter sales results.</li>
<li>Ibotta, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) shares fell 22.9% to $57.75 in pre-market trading after the company reported quarterly results.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) fell 18.7% to $0.3658 in pre-market trading after gaining around 10% on Wednesday.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) dipped 18.3% to $0.0850 in pre-market trading after the company reported a 1-for-50 reverse stock split.</li>
<li>Matinas BioPharma Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#NYSE">MTNB</a>) shares dipped 15.9% to $0.5969 in pre-market trading after falling around 5% on Wednesday.</li>
<li>ESS Tech, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) fell 13.8% to $7.68 in pre-market trading following third-quarter results.</li>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) fell 10.8% to $1.9700 in pre-market trading following third-quarter results.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 10.1% to $18.27 in today's pre-market trading. Super Micro Computer shares fell 6% on Wednesday after the company announced it was unable to file its quarterly report for the period ending Sept. 30 in a timely manner.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

BJDX

BURU

CLDI

DBGI

EFSH

ELAB

HROW

IBTA

MTNB

QBTS

QUBT

SMCI

SVMH

TSHA

XTIA

ZCAR

ZETA

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

Offerings

Cyclacel Pharmaceuticals Announces Exercise Of Warrants For $2.1M, Has Entered Into A Definitive Agreement For The Exercise Of Certain Existing Warrants To Purchase An Aggregate Of 4,968,945 Shares Of Its Common Stock Having An Original Exercise Price Of $1.36 Per Share, Originally Issued In May 2024, At A Reduced Exercise Price Of $0.415 Per Share

Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

Shares of Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/general/space/24/11/41922070/rocket-lab-q3-earnings-revenue-beat-eps-beat-continued-strong-demand-growth-multi-launch-agreement-air-force-award-and-more">third-quarter financial results</a>.
The company also announced a multi-launch agreement with a confidential commercial satellite constellation operator and was awarded a federal defense contract worth up to $8 million.
Rocket Lab USA shares jumped 28.7% to $18.86 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 79.5% to $0.3244 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 62.6% to $0.6682 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) rose 56% to $0.1337 in pre-market trading. Nature&#8217;s Miracle announced the closing of $3.0 million public offering.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) gained 37.3% to $86.21 in pre-market trading after the company reported a profit for the third quarter.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) climbed 27.8% to $34.02 in pre-market trading following strong earnings and guidance.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) gained 26.1% to $2.59 in pre-market trading after jumping 51% on Tuesday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 20.1% to $3.58 in pre-market trading. Mullen Automotive shares jumped 74% on Tuesday after the company announced its Class 1 EV cargo van is listed for vehicle rental on Turo.</li>
<li>WM Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) rose 19.9% to $0.8585 in pre-market trading after the company reported better-than-expected third-quarter revenue results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) gained 14.2% to $11.93 in pre-market trading following third-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares tumbled 81% to $0.5199 in pre-market trading after the company announced its SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint and has discontinued the study.</li>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) shares fell 62.4% to $1.21 in pre-market trading after the company failed to file its earnings for the quarter ended September 2024. The discount airline in a filing late Tuesday, said that it is in talks with its creditors to carve out a restructuring plan which could lead to the cancellation of its equity shares.</li>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) declined 44.8% to $1.24 in pre-market trading after the company priced its $7 million public offering of 5.6 million common shares at $1.25 each.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares fell 43% to $0.6100 in pre-market trading after dipping 46% on Tuesday.</li>
<li>Vroom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) fell 32.8% to $5.96 in pre-market trading following third-quarter results.</li>
<li>Nano Labs Ltd  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) dipped 23.3% to $5.90 in pre-market trading after jumping 134% on Tuesday. The company recently said it will start accepting payments in Bitcoin.</li>
<li>i-80 Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#NYSE">IAUX</a>) fell 21.3% to $0.7150 in pre-market trading after posting third-quarter results.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares dipped 21.4% to $8.90 in pre-market trading after reporting third-quarter results.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) fell 21.2% to $1.60 in today's pre-market trading after jumping over 76% on Tuesday.</li>
<li>ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) fell 13.8% to $11.28 in pre-market trading following third-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41929909/dow-sp-decline-ahead-of-key-inflation-data-tesla-trump-media-slides-fear-index-remains-in-greed-zone">Dow, S&amp;P Decline Ahead Of Key Inflation Data, Tesla, Trump Media Slides: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

DAVE

GRPN

HNRG

IAUX

KAPA

MAPS

MULN

MVST

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

RKLB

SAVE

SIDU

SYRS

Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.56) by 67.86 percent. The company reported quarterly sales of $10.000 thousand which beat the analyst consensus estimate of $5.000 thousand by 100.00 percent.

Earnings Beats

Cyclacel Pharmaceuticals Q3 2024 GAAP EPS $(0.18) Beats $(0.56) Estimate, Sales $10.000K Beat $5.000K Estimate

Cyclacel Pharmaceuticals Requests SEC For Withdrawal Of Registration, Due To Decision Not To Pursue Public Offering

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 124.5% to $1.3 during Monday's regular session. The market value of their outstanding shares is at $7.3 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares increased by 117.99% to $10.66. The market value of their outstanding shares is at $654.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 69.81% to $9.0. The company's market cap stands at $6.6 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 44.51% to $6.72. The company's market cap stands at $87.4 million. </li>
<li>EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) shares moved upwards by 36.31% to $12.95. The market value of their outstanding shares is at $693.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares increased by 30.8% to $2.59. The company's market cap stands at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares fell 18.3% to $4.91 during Monday's regular session. The company's market cap stands at $25.5 million. </li>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock decreased by 15.92% to $26.63. The market value of their outstanding shares is at $24.8 billion. The company's, Q3 earnings came out today. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 14.11% to $2.62. The company's market cap stands at $447.0 million. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares decreased by 13.83% to $1.62. The market value of their outstanding shares is at $36.7 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 12.85% to $0.73. The company's market cap stands at $1.4 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares declined by 12.73% to $1.44. The market value of their outstanding shares is at $7.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVOK

EYPT

GLUE

GNPX

HCTI

ITRM

SONN

TVGN

12 Health Care Stocks Moving In Monday's Intraday Session

Press Releases

General

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Financing

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Comments

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (CYCC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL